DeCure's autonomous Immuno AI scientist is researching a drug-repurposing hypothesis for immunodeficiency, common variable, 10 — screening already-approved drugs against its 3-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleImmunodeficiency, common variable, 10 maps to a 3-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for immunodeficiency, common variable, 10 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
stromal interaction molecule 1 (STIM1) — STIM1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet apo structuredrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 4O9B · 2.604 Å · ligand none (apo structure). Experimental structure, not a prediction.
What the evidence adds up to
A 2002 prospective cohort study of 288 antiretroviral-naive HIV patients who maintained complete virus suppression for at least 24 months found that 42 of 255 patients (16.5%) had a median CD4+ cell count increase of less than 100 x 10^6 cells/L after 24 months. Previous injection drug use was associated with this poor immune recovery (risk ratio 2.326, 95% CI 1.077-5.023, p=0.032). Inclusion of a protease inhibitor in the regimen reduced the risk (risk ratio 0.160, 95% CI 0.061-0.417, p<0.001). The study concerns HIV, not common variable immunodeficiency.
A 2023 review describes common variable immunodeficiency disorders (CVID) as the most common symptomatic primary immunodeficiency, noting that diagnosis is challenging because symptoms are non-specific and heterogeneous. The review covers clinical symptoms, complications, and management but provides no quantitative data on treatment outcomes or specific drug effects.
A 2013 textbook chapter on primary immunodeficiency lists common variable immunodeficiency (CVID) under B-lymphocyte disorders and mentions complications and treatment, but gives no numerical results from any trial or study.
No abstract provides evidence for any drug repurposing in CVID. No response rates, survival data, or sample sizes for any treatment in CVID are reported. What is missing is any controlled trial testing a specific drug in CVID patients, any biomarker to stratify the heterogeneous CVID population, and funding for such a trial.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Long‐Term Outcomes among Antiretroviral‐Naive Human Immunodeficiency Virus–Infected Patients with Small Increases in CD4<sup>+</sup>Cell Counts after Successful Virologic Suppression
AbstractTo evaluate the frequency and predictive factors of discordant immune response, we performed a prospective cohort study of 288 antiretroviral-naive human immunodeficiency virus (HIV)-infected patients who initiated highly active antiretroviral therapy (HAART) and maintained complete virus suppression for > or =24 months. The median CD4+ cell count was 186x10(6) cells/L, and the median HIV RNA level was 5 log(10) copies/mL. After 24 months of therapy, 42 (16.5%) of 255 patients had a median CD4+ cell count increase of <100x10(6) cells/L. By logistic regression analysis, previous injection drug use was associated with a CD4+ cell count increase of <100x10(6) cells/L (risk ratio [RR], 2.326; 95% confidence interval [CI], 1.077-5.023; P=.032); inclusion of a protease inhibitor (PI) in the HAART regimen reduced the risk of poor immunologic recovery (RR, 0.160; 95% CI, 0.061-0.417; P<.001). Failure of the CD4+ cell count to increase was relatively common among antiretroviral-naive patients in the year after the initiation of HAART and the achievement of complete virus suppression. PI-containing regimens provided better immunologic response.
Malaysian Journal of Paediatrics and Child Health · 2023 · 0 citations · open access
Common Variable Immunodeficiency: A Paradox of Immunodeficiency and Autoimmunity
AbstractCommon variable immunodeficiency disorders (CVID) are the most common form of symptomatic primary immunodeficiency. The diagnosis of CVID can be challenging as the symptoms are non-specific and heterogenous in nature. In light of this, a broad review of this disease is presented here based on the important clinical symptoms, complications and management.
Oxford University Press eBooks · 2013 · 0 citations
Primary immunodeficiency
AbstractIntroduction Classification of immunodeficiency Clinical features of immunodeficiency Investigation of immunodeficiency Laboratory investigation Major B-lymphocyte disorders Rare antibody deficiency syndromes X-linked agammaglobulinaemia (Bruton’s disease) Common variable immunodeficiency (CVID) CVID 2: complications and treatment Selective IgA deficiency IgG subclass deficiency Specific antibody deficiency with normal serum immunoglobulins...
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
